Over the past 25 years, HIV has emerged as a pressing threat to human health. HIV has already cost 25 million human lives, and an estimated 2 million people continue to die every year as a result of AIDS (UNAIDS, 2007) . Although the HIV pandemic continues to expand, the retrovirus itself is a surprisingly weak pathogen in terms of its overall infectivity: in vitro, only one in every 1,000 to 100,000 viral particles is infectious (Dimitrov et al., 1993; Rusert et al., 2004) . What explains the discrepancy between the low infectivity of HIV virions in vitro and the high incidence of new infections worldwide? The answer may lie in part with host factors that potentiate the person-toperson spread of HIV. In this issue, Münch et al. (2007) provide support for this notion by detecting a human factor in semen that under certain circumstances can enhance HIV infectivity by more than five orders of magnitude.
The most common mode of HIV transmission is sexual contact between a male donor and a female recipient, with semen serving as the infectious fluid. An attractive hypothesis is that semen contains one or more factors that protect HIV virions or enhance their transmission. This hypothesis is strengthened by the observation that replication-competent HIV can be detected in semen even when antiretroviral drugs are present at 10-fold higher concentrations in seminal fluid than in blood (Pomerantz, 2003) . Indeed, a number of components of seminal fluid, whose physiological purpose is to protect spermatozoa during their journey to a female's egg, can also protect HIV virions. For example, basic amines such as spermine, spermidine, putrescine, and cadaverine commonly protect both spermatozoa and HIV virions from the threat of acid inactivation in the vaginal tract. In addition to amines, seminal fluid contains a variety of nutrients and enzymes produced by the prostate, seminal vesicles, and bulbourethal glands. Proteomic analysis of seminal fluid has identified more than 900 proteins (Fung et al., 2004; Pilch and Mann, 2006; Starita-Geribaldi et al., 2001) . One or more of these proteins might also influence the efficiency of HIV transmission.
In their new findings, Münch et al. not only demonstrate that semen does enhance HIV infectivity, but they further identify and characterize a specific peptide that contributes to this activity. From a complex peptide/protein library prepared from pooled human semen, they identified a fraction that consistently enhanced HIV infectivity. Sequencing and mass spectroscopic analysis of this fraction revealed the enhancing factors to be peptide fragments generated from an internal region of prostatic acid phosphatase (PAP), a protein produced by the prostate and secreted into semen in milligram quantities. The major peptide in the enhancing fraction, residues 248-286 from PAP, is present at a concentration of ~35 µg/ml in pooled semen samples. At concentrations ≥0.8 µg/ml, chemically synthesized PAP248-286 broadly enhances infection by R5-, X4-, and dual-tropic HIV-1 strains as well as more divergent group M and O strains. Furthermore, the peptide enhances both direct and trans-infection of multiple cell lines and primary cells isolated from human tonsillar tissue and peripheral blood.
Remarkably, when the effects of the peptide are assessed under conditions of limiting viral inoculum, the enhancement of viral infectivity can exceed five orders of magnitude. By calculating the number of virions in their virus stocks, Münch et al. conclude that only one to three virions are sufficient for productive HIV infection in the presence of physiological concentrations of the semen-derived peptide. Conversely, in the absence of the peptide, 1,000-100,000 HIV particles are typically necessary to observe productive infection (Münch et al., 2007) . These findings raise the possibility that the low ratio of infectious to noninfectious virions found in most viral samples could relate more to the ineffective delivery of virions to target cells (Thomas et al., 2007) Although the worldwide incidence of HIV infection is high, the retrovirus displays a surprisingly low infectivity in vitro. As a potential explanation for this discrepancy, Münch et al. (2007) now identify and characterize a factor found in human semen that under certain conditions can enhance HIV infectivity by more than 100,000-fold.
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Intriguingly, the story contains a further twist that was discovered serendipitously. With the sequence of the peptide in hand, Münch and colleagues chemically synthesized PAP248-286 and tested it for enhancing activity. Surprisingly, the freshly synthesized peptide was completely inactive. However, when the peptide was retested after either short-term storage or agitation, activity was readily detected. The investigators noted that development of enhancing activity correlated with the appearance of turbidity in the peptide solution. They centrifuged the turbid solution and discovered that the enhancing activity resided entirely within the pelleted fraction. Further analysis employing a variety of biophysical techniques revealed that the turbid PAP248-286 solution was laden with amyloid fibrils. These fibrils appeared to bind to virions and were captured by cellular protrusions, leading to a marked increase in the attachment of the virions to target cells. The authors named these fibrils semen-derived enhancer of viral infection, or SEVI.
Is there a precedent for amyloid fibril-mediated enhancement of HIV infection? Indeed, studies have shown that β-amyloid fibrils can also enhance HIV infection in a coreceptor-dependent manner, albeit with lower efficiency (Wojtowicz et al., 2002) . Therefore, in addition to its widely recognized role in neurodegenerative diseases, the amyloid fold may also play a key role in HIV transmission.
These latest advances establish a model whereby PAP248-286, after proteolytic cleavage from its polypeptide precursor, aggregates to form SEVI amyloid fibrils (Figure 1) . These fibrils bind directly to the HIV virions and enhance their infectivity by efficiently delivering them to target cells to which they fuse. During male-to-female transmission, the major targets of SEVI-coated virions are presumably HIV-permissive cells in the genital mucosa. However, whether SEVI indeed enhances HIV infection of primary cells isolated from the vagina, cervix, and endometrium remains to be determined.
As with most significant advances, this paper raises a whole series of new questions. First, how do SEVI fibrils enhance HIV infectivity? Although improved virion attachment appears to be involved, what properties of SEVI lead to this change? As noted, not all amyloid fibrils equally enhance HIV infection (Münch et al., 2007) , suggesting that the primary sequence of the peptide may be important. Second, how and where is fully active SEVI formed? In particular, the protease that releases PAP248-286 from its polypeptide precursor remains unknown, and the conditions that favor the seeding and amplification of SEVI fibrils are similarly undefined. It is unclear whether these fibrils exist in a completely formed state in semen or alternatively whether the mixing of the basic semen and acidic vaginal fluids accelerates fibril formation. And finally, do SEVI fibrils have a function in normal human reproduction, or are they simply an accident of protein misfolding that unfortunately facilitates HIV infection?
Of note, the overall frequency of heterosexual HIV transmission per sexual act is only about 0.0001 to 0.001, although this frequency increases when viral loads are especially high in the male donor or genital ulcers are present in the female recipient (Gray et al., 2001) . If SEVI truly increases the real world heterosexual spread of HIV by several orders of magnitude, then negating the activity of this factor could conceivably diminish these frequencies to levels that might virtually eliminate semendriven HIV transmission. Such a host-directed strategy for impairing HIV transmission is unlikely to select for the rapid emergence of drugresistant viral strains so characteristic of virus-directed therapies. However, to design ways to inhibit the activity of SEVI, we first need to better understand its mechanisms of generation and action. The future promises a series of rapid and important advances as the SEVI story unfolds further. Prostatic acid phosphatase (PAP), an abundant protein in semen, is cleaved into the PAP248-286 peptide, which then aggregates to form amyloid fibrils termed semen-derived enhancer of viral infection (SEVI) (Münch et al., 2007) . The fibrils capture HIV virions and direct them to target cells to which they fuse. Under conditions of a limiting viral inoculum, SEVI enhances infectivity of HIV virions by more than 100,000-fold
